At the news
? NEUTRALIMPACT 4/10 10-K/A filed Apr 17, 2026 at 16:00 ET
This is an amended 10-K filing by Day One Biopharmaceuticals to include Part II and Part III disclosures that were omitted from the original filing, primarily because the company did not intend to file a proxy statement within 120 days of its fiscal year-end. The amendment includes comprehensive details on executive compensation, board composition, director compensation, and equity plan information. A key event disclosed is the repricing of underwater stock options for executives and directors to $8.99 per share to retain talent, and the filing confirms the company's pending acquisition by Servier Pharmaceuticals.
- The amendment was filed to include required Part II and Part III disclosures omitted from the original 10-K, not due to financial restatements or errors.
- The company's pending acquisition by Servier Pharmaceuticals was announced on March 6, 2026, which explains the lack of a proxy statement.
- An option repricing event occurred on November 6, 2025, reducing the exercise price of underwater options for executives and directors from prices as high as $23.41 to $8.99 per share, the then-current market price, to retain talent.
- CEO Jeremy Bender's total compensation for 2025 was $9.1 million, with a CEO-to-median-employee pay ratio of 24:1.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access